Hilde Berner Hammer Selected Research

1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedione

5/2021

Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hilde Berner Hammer Research Topics

Disease

26	Rheumatoid Arthritis 01/2023 - 08/2007
15	Inflammation (Inflammations) 01/2023 - 02/2002
8	Gout 02/2024 - 11/2020
7	Pain (Aches) 03/2024 - 09/2017
5	Synovitis 10/2018 - 01/2011
4	Osteoarthritis 03/2024 - 01/2013
4	Fatigue 03/2022 - 11/2020
3	Necrosis 01/2023 - 01/2017
3	Arthralgia (Joint Pain) 03/2022 - 11/2017
3	Rheumatic Diseases (Rheumatism) 12/2017 - 08/2007
1	Chondrocalcinosis (Pseudogout) 02/2024
1	Musculoskeletal Pain 12/2022
1	Chronic Disease (Chronic Diseases) 03/2022
1	Disease Progression 09/2021
1	Bursitis (Adhesive Capsulitis) 01/2019
1	Psoriatic Arthritis 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2015
1	Osteophyte 01/2013
1	Joint Diseases (Joint Disease) 08/2011
1	Churg-Strauss Syndrome (Allergic Angiitis) 02/2002
1	Bronchial Spasm 02/2002

Drug/Important Bio-Agent (IBA)

13	Antirheumatic Agents (DMARD)IBA 01/2023 - 01/2015
8	Biomarkers (Surrogate Marker)IBA 03/2024 - 08/2007
8	Uric Acid (Urate)IBA 12/2023 - 11/2016
8	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2023 - 08/2007
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2007
4	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 01/2017
4	Adalimumab (Humira)FDA Link 10/2014 - 07/2010
3	C-Reactive ProteinIBA 01/2023 - 12/2017
3	Prostaglandins AIBA 11/2022 - 01/2022
3	Rheumatoid FactorIBA 11/2020 - 01/2011
2	Rituximab (Mabthera)FDA Link 01/2023 - 01/2015
2	tocilizumab (atlizumab)FDA Link 03/2022 - 01/2015
2	S100A12 ProteinIBA 12/2017 - 10/2014
1	calcium phosphateIBA 02/2024
1	oxidized low density lipoproteinIBA 12/2023
1	HDL CholesterolIBA 12/2023
1	LipidsIBA 12/2023
1	amsonic acid (DAS)IBA 01/2022
1	Allopurinol (Remid)FDA LinkGeneric 01/2022
1	Colchicine FDA LinkGeneric 01/2022
1	Etanercept (Enbrel)FDA Link 12/2021
1	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 05/2021
1	Anti-Citrullinated Protein AntibodiesIBA 11/2020
1	cyclic citrullinated peptideIBA 01/2019
1	Edetic Acid (EDTA)FDA Link 02/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2017
1	Interleukin-6 (Interleukin 6)IBA 12/2017
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 11/2017
1	Abatacept (Orencia)FDA Link 01/2015
1	Calcium-Binding ProteinsIBA 10/2014
1	4-hexyloxyaniline (HOA)IBA 01/2013
1	Infliximab (Remicade)FDA Link 08/2011
1	S100 Proteins (S 100 Protein)IBA 01/2011
1	AntibodiesIBA 01/2011
1	LeukotrienesIBA 02/2002
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 02/2002
1	montelukast (Singulair)FDA Link 02/2002
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2002
1	zafirlukast (Accolate)FDA LinkGeneric 02/2002
1	pranlukastIBA 02/2002

Therapy/Procedure

10	Therapeutics 12/2023 - 08/2011
1	Precision Medicine 01/2023
1	Arthroplasty 12/2022
1	Pain Management 01/2022
1	Biological Therapy 01/2022
1	Aftercare (After-Treatment) 02/2002